Nakiki SE plans strategic realignment toward a "pure" Bitcoin treasury strategy
Article content
FRANKFURT AM MAIN, Germany — Nakiki SE (ISIN: DE000WNDL300) is planning a strategic realignment with the aim of becoming the first German listed company with a pure Bitcoin treasury strategy. A Bitcoin treasury strategy means that a company focuses its investments on Bitcoin. The course for building a Bitcoin portfolio was set today following discussions with potential investors, placing banks, and Bitcoin experts. At the annual general meeting to be held in the second half of 2025, a change of name will be proposed in addition to an adjustment of the company's purpose. In addition, discussions are being held with anchor investors to secure the funds required to finance the Bitcoin portfolio through capital increases.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901. A replay of the call will also be available on the Enovis website later that day. About Enovis Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Availability of Information on the Enovis Website Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares at Contact:
Globe and Mail
30 minutes ago
- Globe and Mail
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the 'Vertex Pharmaceuticals Second Quarter 2025 Earnings Call.' The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
Globe and Mail
31 minutes ago
- Globe and Mail
BrightSpring Health Services, Inc. to Announce Second Quarter 2025 Financial Results on August 1, 2025
LOUISVILLE, Ky., July 08, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ('BrightSpring' or the 'Company') (NASDAQ: BTSG) announced today that it plans to release its second quarter 2025 financial results on Friday, August 1, 2025, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day. To participate in the conference call, please register here before the 8:30 a.m. ET start. A live and archived webcast of the call will be available on the Company's investor relations website at under the 'Events & Presentations' section, where related presentation materials will be posted prior to the conference call. The webcast may be accessed directly here. About BrightSpring Health Services BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system. Contact Investor Relations: David Deuchler, CFA Gilmartin Group LLC ir@ Media Contact: Leigh White 502.630.7412
